GlassScriptPhysician profile
Fouad Jabbour
NPI 1205368883
$9,417.94
in general payments reported to CMS, 2019-2025
25 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,064 · 2022: $1,039 · 2023: $2,321 · 2024: $3,492 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,662 · Grant: $1,063 · Travel and Lodging: $588 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,662.28 |
| Grant | $1,063.30 |
| Travel and Lodging | $587.97 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,164.93 | 2023-2025 | Avvigo Guidance System, Watchman Flx, Opticross |
| Edwards Lifesciences Corporation | $1,146.96 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abiomed | $1,039.77 | 2021-2025 | Impella |
| Abbott Laboratories | $812.59 | 2021-2025 | Diamondback Coronary, Coroflow, Amplatzer Amulet |
| W. L. Gore & Associates, INC. | $596.57 | 2021-2024 | Gore Cardioform Septal Occluder |
| Medtronic, INC. | $513.80 | 2023-2024 | Corevalve Evolut R |
| Heartflow, INC. | $429.65 | 2023-2025 | Ffrct |
| Teleflex LLC | $406.72 | 2023 | Guideliner, Spectre |
| Amgen INC. | $385.78 | 2021-2023 | Repatha |
| Shockwave Medical, INC | $300.63 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.44 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $245.07 | 2021-2023 | Farxiga |
| Inari Medical, INC. | $183.22 | 2021 | |
| Cardiovascular Systems INC. | $133.94 | 2022 | |
| Penumbra, INC. | $111.06 | 2023 | Indigo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $107.25 | 2022 | |
| Cordis US Corp. | $102.06 | 2023 | Mynx Control |
| Kiniksa Pharmaceuticals, LTD. | $95.64 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.23 | 2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $78.52 | 2023-2024 | Xarelto |
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Terumo Medical Corporation | $66.91 | 2022-2023 | Tr Band, Heartrail, Glidewire |
| Novo Nordisk INC | $20.23 | 2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $17.10 | 2024 | |
| Cardiva Medical, INC. | $14.87 | 2025 | Savvywire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Jabbour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.